Close
New

Medscape is available in 5 Language Editions – Choose your Edition here.

 

Pediatric Heart Transplantation Medication

  • Author: Richard E Chinnock, MD; more...
 
Updated: Nov 13, 2014
 

Medication Summary

The goals of pharmacotherapy are to prevent complications, to reduce morbidity, and to reduce the chances for organ rejection.

Optimal therapy includes sedation, vasodilator therapy, alkalization through hyperventilation, inotropic agents with minimal pulmonary vasoconstrictive effects, and inhaled nitric oxide, when available. Sildenafil has also been used in this setting.

Next

Vasodilators

Class Summary

These agents relax blood vessels and cause a decrease peripheral vascular resistance.

Sodium nitroprusside (Nitropress)

 

Sodium nitroprusside produces vasodilation and increases inotropic activity of the heart.

Nitroglycerin (Nitro-Bid, Nitro-Dur, Minitran)

 

Nitroglycerin causes relaxation of vascular smooth muscle by stimulating intracellular cyclic guanosine monophosphate (cGMP) production, resulting in a decrease in blood pressure.

Previous
Next

Inotropic Agents

Class Summary

After the procedure, the patient is maintained on a combination of pressor agents while the donor heart regains energy stores. Once stabilized, the patient is rapidly weaned from the ventilator and the pressors. The chosen combination depends on the training and experience of the transplantation center.

Dopamine

 

Dopamine is a naturally occurring endogenous catecholamine that stimulates beta1-and alpha1-adrenergic and dopaminergic receptors in a dose-dependent fashion. It stimulates release of norepinephrine.

In low doses (2-5 μg/kg/min), dopamine acts on dopaminergic receptors in renal and splanchnic vascular beds, causing vasodilatation in these beds. In midrange doses (5-15 μg/kg/min), it acts on beta-adrenergic receptors to increase heart rate and contractility. In high doses (15-20 μg/kg/min), it acts on alpha-adrenergic receptors to increase systemic vascular resistance and raise blood pressure.

Dobutamine

 

Dobutamine is a sympathomimetic amine with stronger beta than alpha effects. It increases the inotropic state. Vasopressors augment the coronary and cerebral blood flow during the low-flow state associated with severe hypotension.

Dopamine and dobutamine are the drugs of choice to improve cardiac contractility, with dopamine the preferred agent in hypotensive patients. Higher dosages may cause an increase in heart rate, exacerbating myocardial ischemia.

Epinephrine (Adrenalin)

 

Its alpha-agonist effects include increased peripheral vascular resistance, reversed peripheral vasodilatation, systemic hypotension, and vascular permeability. Its beta2-agonist effects include bronchodilation, chronotropic cardiac activity, and positive inotropic effects.

Norepinephrine (Levophed)

 

Norepinephrine stimulates beta1- and alpha-adrenergic receptors, increasing cardiac muscle contractility and heart rate, as well as vasoconstriction; this results in systemic blood pressure and coronary blood flow increases. After obtaining a response, the rate of flow should be adjusted and maintained at a low-normal blood pressure, such as 80-100 mm Hg systolic, sufficient to perfuse vital organs.

Previous
Next

Pulmonary Vasodilators

Class Summary

Inhaled nitric oxide (NO) is a pulmonary vasodilator indicated for pulmonary hypertension. NO is also being studied for severe hypoxemia in acute respiratory distress syndrome (ARDS).

Nitric oxide, inhaled (INOmax)

 

NO is produced endogenously from the action of the enzyme NO synthetase on arginine. It relaxes vascular smooth muscle by binding to the heme moiety of cytosolic guanylate cyclase, activating guanylate cyclase and increasing intracellular levels of cyclic guanosine monophosphate (cGMP), which then leads to vasodilation. When inhaled, NO decreases pulmonary vascular resistance and improves lung blood flow.

Previous
Next

Phosphodiesterase Type 5 Inhibitors

Class Summary

Phosphodiesterase type 5 (PDE5) inhibitors are used to treat pulmonary hypertension.

Sildenafil (Revatio)

 

Sildenafil promotes selective smooth muscle relaxation in lung vasculature, possibly by inhibiting PDE5. This results in a subsequent reduction of blood pressure in pulmonary arteries and an increase in cardiac output.

Previous
Next

Immunosuppressants

Class Summary

A number of protocols exist for immunosuppression in the perioperative and postoperative period. The most appropriate initial immunosuppression protocol is not known. Every transplantation center likely has a different protocol. Clear data are difficult to obtain because of the small number of transplantations performed each year and the need for centers to standardize practice across institutions. Below are the immunosuppressants used at Loma Linda University Children’s Hospital.

Cyclosporine (Neoral, Sandimmune, GENGRAF)

 

Cyclosporine is a cyclic polypeptide that suppresses some humoral immunity and, to a greater extent, cell-mediated immune reactions such as delayed hypersensitivity, allograft rejection, experimental allergic encephalomyelitis, and graft versus host disease for various organs.

For children and adults, base dosing on ideal body weight. Maintaining appropriate levels of the drug in the bloodstream is crucial to the maintenance of the allograft. Foods can alter the level of the drug and time of administration. Medication must be taken at the same time every day.

Neoral is the capsular form of cyclosporine, available in 25- and 100-mg capsules. Sandimmune is the liquid form. GENGRAF is the branded generic form, available in 25- and 100-mg capsules.

Cyclosporine is begun at 0.1 mg/kg/h IV when the donor is identified, stopped during the procedure, and restarted after transplantation; this is switched to oral dosing when possible, with a target trough cyclosporine level of 250-300 ng/mL

Methylprednisolone (Medrol, Solu-Medrol, Depo-Medrol)

 

Methylprednisolone decreases inflammation by suppressing the migration of polymorphonuclear leukocytes and reversing increased capillary permeability.

At Loma Linda, acute rejection is treated with IV methylprednisolone at 20 mg/kg (not to exceed a dose of 500 mg) twice daily for 8 doses. Uncomplicated rejection diagnosed on the basis of biopsy findings alone may be treated with oral prednisone at 2 mg/kg/day for 3 days, with a taper to zero over 3 weeks.

Mycophenolate mofetil (CellCept, Myfortic)

 

Mycophenolate mofetil, a derivative of mycophenolic acid (MPA), blocks the de novo pathway of guanosine nucleotide synthesis by inhibiting the activity of inosine monophosphate dehydrogenase and thus inhibiting de novo purine synthesis. Both T and B lymphocytes are highly dependent on the de novo pathway, whereas other cells use the purine salvage pathway of nucleotide synthesis. As a result, MPA selectively inhibits lymphocyte activity. At Loma Linda, mycophenolate mofetil is given as part of the primary immunosuppression regimen. Dosing begins at 300 mg/m2/day divided into 2 doses and is increased as tolerated to maintain a mycophenolic acid level of 2.5-5 µg/mL

Mycophenolate mofetil is administered IV or orally at 500 mg/m2 twice daily; dosing is adjusted as necessary to maintain a mycophenolate mofetil level of 2.5-5 µg/mL and a white blood cell (WBC) count of at least 4 × 109/L

Prednisone

 

Prednisone is an immunosuppressant used for treatment of autoimmune disorders. It may decrease inflammation by reversing increased capillary permeability and suppressing polymorphonuclear (PMN) leukocyte activity. It is an oral steroid with approximately 5 times the potency of endogenous steroids. Minimal to no oral prednisone should be given for the first 21 days after transplantation unless rejection occurs.

Programs that use steroids typically start with oral prednisone at a dosage of 2 mg/kg/day and then wean over the first 3 months to a maintenance regimen of 0.1-0.3 mg/kg once daily or once every other day.

Tacrolimus (Prograf)

 

Tacrolimus suppresses humoral immunity (T-cell activity). It is a calcineurin inhibitor with 2-3 times the potency of cyclosporine. Tacrolimus can be used at lower doses than cyclosporine, but it has severe adverse effects, including renal dysfunction, diabetes, and pancreatitis. Levels are adjusted according to renal function, hepatic function, and adverse effects.

In children, tacrolimus bioavailability is about 31%, though whole-blood concentrations in a study of 31 children younger than 12 years indicate that children require higher doses than adults to achieve similar trough concentrations. A high-fat meal reduces the mean area under the curve (AUC) by 37%, whereas a high-carbohydrate meal decreases the mean AUC by 28%. Peak concentrations are also reduced by 77% and 65%, respectively.

Tacrolimus is not commercially available as a liquid preparation; the solution must be compounded in a local pharmacy.

Azathioprine (Imuran, Azasan)

 

Azathioprine antagonizes purine metabolism and inhibits synthesis of DNA, RNA, and proteins. It may decrease the proliferation of immune cells, which results in lower autoimmune activity. Antimetabolites are used to block the uptake of vital nutrients needed by the cells. As implied, these drugs affect not only the cells of the immune system but also other cells of the body. The potency of therapy is dose dependent. Azathioprine is not effective treatment for acute rejection episodes but remains an economical choice for long-term immunosuppression.

Among the antiproliferative agents, azathioprine has been the therapeutic mainstay. According to the ISHLT, however, mycophenolate mofetil is now used in approximately 60% of pediatric patients who receive a heart transplant. Again, no prospective studies are available.

Sirolimus (Rapamune)

 

Sirolimus, also known as rapamycin, is a macrocyclic lactone produced by Streptomyces hygroscopicus. It is a potent immunosuppressant that inhibits T-cell activation and proliferation by a mechanism that is distinct from that of all other immunosuppressants. This inhibition suppresses cytokine-driven T-cell proliferation by inhibiting progression from the G1 phase to the S phase in the cell cycle.

Sirolimus is a newer agent that works synergistically with calcineurin inhibitors. There is little published experience with this agent in pediatric heart transplantation, but what is available seems to indicate some usefulness in the management of rejection, renal dysfunction, and calcineurin adverse effects.

Lymphocyte immune globulin, equine (Atgam)

 

This agent inhibits the cell-mediated immune response by altering T-cell function or by eliminating antigen-reactive cells.

There is little prospective, randomized data to suggest a single schedule that is superior, but experience suggests that a short infusion is best tolerated.

At Loma Linda, antithymocyte globulin 1.5 mg/kg/day is administered by slow IV administration over 6 hours. This dosage is continued for 7-10 days. A lymphocyte profile should be obtained on day 3, with a target absolute CD3 count of less than 200 cells/mL. The use of high-dose IV immunoglobulin in the treatment of graft rejection may be beneficial.

Previous
Next

Immune Globulins

Class Summary

Intravenous immunoglobulin (IVIG) is the usual choice. It is derived from human plasma and is composed of all 4 immunoglobulin G (IgG) subclasses.

Intravenous immunoglobulin (IVIG; Carimune Gammagard S/D, Gamunex-C, Octagam)

 

IVIG uses anti-idiotypic antibodies to neutralize circulating myelin antibodies. IVIG down-regulates proinflammatory cytokines, including interferon-gamma. It blocks Fc receptors on macrophages, suppresses inducer T cells and B cells, and augments suppressor T cells. In addition, IVIG blocks the complement cascade, promotes remyelination, and may increase cerebrospinal fluid (CSF) IgG (10%).

Previous
 
Contributor Information and Disclosures
Author

Richard E Chinnock, MD Medical Director of Pediatric Heart Transplant Program, Professor and Chair, Department of Pediatrics, Loma Linda University School of Medicine and Children's Hospital

Richard E Chinnock, MD is a member of the following medical societies: American Academy of Pediatrics, American Heart Association, American Medical Association, American Society of Transplantation, California Medical Association, Western Society for Pediatric Research, Transplantation Society, International Society for Heart and Lung Transplantation, Society for Pediatric Research

Disclosure: Received grant/research funds from Roche Pharmaceuticals for other.

Acknowledgements

Richard G Ohye, MD Head, Division of Pediatric Cardiovascular Surgery; Program Director, Pediatric Cardiac Surgery Fellowship, University of Michigan Medical Center

Richard G Ohye, MD is a member of the following medical societies: Alpha Omega Alpha, American Association for Thoracic Surgery, American College of Cardiology, American College of Chest Physicians, American College of Surgeons, Association for Academic Surgery, Congenital Heart Surgeons Society, International Society for Heart and Lung Transplantation, Society of Thoracic Surgeons, and Society of University Surgeons

Disclosure: Nothing to disclose.

Mary L Windle, PharmD Adjunct Associate Professor, University of Nebraska Medical Center College of Pharmacy; Editor-in-Chief, Medscape Drug Reference

Disclosure: Nothing to disclose.

References
  1. Dipchand AI, Edwards LB, Kucheryavaya AY, Benden C, Dobbels F, Levvey BJ, et al. The registry of the international society for heart and lung transplantation: seventeenth official pediatric heart transplantation report-2014; focus theme: retransplantation. J Heart Lung Transplant. 2014 Oct. 33(10):985-95. [Medline].

  2. Fenton MJ, Chubb H, McMahon AM, et al. Heart and heart-lung transplantation for idiopathic restrictive cardiomyopathy in children. Heart. 2006 Jan. 92(1):85-9. [Medline].

  3. Chrisant MR, Naftel DC, Drummond-Webb J, et al. Fate of infants with hypoplastic left heart syndrome listed for cardiac transplantation: a multicenter study. J Heart Lung Transplant. 2005 May. 24(5):576-82. [Medline].

  4. Canter CE, Shaddy RE, Bernstein D, et al. Indications for heart transplantation in pediatric heart disease: a scientific statement from the American Heart Association Council on Cardiovascular Disease in the Young; the Councils on Clinical Cardiology, Cardiovascular Nursing, and Cardiovascular Surgery and Anesthesia; and the Quality of Care and Outcomes Research Interdisciplinary Working Group. Circulation. 2007 Feb 6. 115(5):658-76. [Medline]. [Full Text].

  5. Godown J, Donohue JE, Yu S, Friedland-Little JM, Gajarski RJ, Schumacher KR. Differential effect of body mass index on pediatric heart transplant outcomes based on diagnosis. Pediatr Transplant. 2014 Nov. 18(7):771-6. [Medline].

  6. Cohen A, Addonizio LJ, Softness B, et al. Growth and skeletal maturation after pediatric cardiac transplantation. Pediatr Transplant. 2004 Apr. 8(2):126-35. [Medline].

  7. Moll S, Pascual M. Humoral rejection of organ allografts. Am J Transplant. 2005 Nov. 5(11):2611-8. [Medline].

  8. Das B, Shoemaker L, Recto M, Austin E, Dowling R. Alemtuzumab (Campath-1H) induction in a pediatric heart transplant: successful outcome and rationale for its use. J Heart Lung Transplant. 2008 Feb. 27(2):242-4. [Medline].

  9. Di Filippo S, Boissonnat P, Sassolas F, et al. Rabbit antithymocyte globulin as induction immunotherapy in pediatric heart transplantation. Transplantation. 2003 Feb 15. 75(3):354-8. [Medline].

  10. Eisen HJ, Kobashigawa J, Keogh A, et al. Three-year results of a randomized, double-blind, controlled trial of mycophenolate mofetil versus azathioprine in cardiac transplant recipients. J Heart Lung Transplant. 2005 May. 24(5):517-25. [Medline].

  11. Morrow WR, Parker JG, Naftel DC. Adjunctive mycophenolate vs. azathioprine for prevention of rejection in pediatric heart transplant recipients. J Heart Lung Transplant. 2005. 24(2S):S113.

  12. Barr ML, Meiser BM, Eisen HJ, et al. Photopheresis for the prevention of rejection in cardiac transplantation. Photopheresis Transplantation Study Group. N Engl J Med. 1998 Dec 10. 339(24):1744-51. [Medline].

  13. Behera SK, Trang J, Feeley BT, Levi DS, Alejos JC, Drant S. The use of Doppler tissue imaging to predict cellular and antibody-mediated rejection in pediatric heart transplant recipients. Pediatr Transplant. 2008 Mar. 12(2):207-14. [Medline].

  14. Bennhagen RG, Sornmo L, Pahlm O, Pesonen E. Serial signal-averaged electrocardiography in children after cardiac transplantation. Pediatr Transplant. 2005 Dec. 9(6):773-9. [Medline].

  15. Stewart S, Winters GL, Fishbein MC, et al. Revision of the 1990 working formulation for the standardization of nomenclature in the diagnosis of heart rejection. J Heart Lung Transplant. 2005 Nov. 24(11):1710-20. [Medline].

  16. Balfour IC, Fiore A, Graff RJ, Knutsen AP. Use of rituximab to decrease panel-reactive antibodies. J Heart Lung Transplant. 2005 May. 24(5):628-30. [Medline].

  17. Katz BZ, Pahl E, Crawford SE, et al. Case-control study of risk factors for the development of post-transplant lymphoproliferative disease in a pediatric heart transplant cohort. Pediatr Transplant. 2007 Feb. 11(1):58-65. [Medline].

  18. Webber SA, Naftel DC, Fricker FJ, et al. Lymphoproliferative disorders after paediatric heart transplantation: a multi-institutional study. Lancet. 2006 Jan 21. 367(9506):233-9. [Medline].

  19. Balfour IC, Srun SW, Wood EG, Belsha CW, Marshall DL, Ferdman BR. Early renal benefit of rapamycin combined with reduced calcineurin inhibitor dose in pediatric heart transplantation patients. J Heart Lung Transplant. 2006 May. 25(5):518-22. [Medline].

  20. Dipchand AI, Edwards LB, Kucheryavaya AY, Benden C, Dobbels F, Levvey BJ, et al. The registry of the international society for heart and lung transplantation: seventeenth official pediatric heart transplantation report-2014; focus theme: retransplantation. J Heart Lung Transplant. 2014 Oct. 33(10):985-95. [Medline].

 
Previous
Next
 
View of the recipient's chest after the heart is removed, with the patient on cardiopulmonary bypass.
 
 
 
All material on this website is protected by copyright, Copyright © 1994-2016 by WebMD LLC. This website also contains material copyrighted by 3rd parties.